Richard M Silver MD
Rheumatoid Arthritis & Related, Scleroderma & Related, Vasculitis
Division of Rheumatology & Immunology, Medical University of South Carolina
Join to view full profile
171 Ashley AveCharleston, SC 29425
Phone+1 843-792-1414
Dr. Silver is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Diego) Medical CenterFellowship, Rheumatology, 1979 - 1981
University of North Carolina HospitalsResidency, Internal Medicine, 1975 - 1977
Vanderbilt University School of MedicineClass of 1975
Certifications & Licensure
CA State Medical License 1979 - Present
SC State Medical License 1981 - 2027
NC State Medical License 1975 - 2002
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
Clinical Trials
Publications & Presentations
PubMed
- Definition, diagnosis, treatment for scleroderma primary heart involvement.DeAnna Baker Frost, Ryan J Tedford, Richard Silver
Best Practice & Research. Clinical Rheumatology. 2026-09-01 - 3 citationsGain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.Urvashi Kaundal, Pei-Suen Tsou, Mousumi Sahu, Mengqi Huang, Steven E Boyden
Annals of the Rheumatic Diseases. 2026-07-01 - 3 citationsCombining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Mult...Dinesh Khanna, Cathie Spino, Donald P Tashkin, Elana J Bernstein, Jonathan Goldin
ACR Open Rheumatology. 2025-12-01
Press Mentions
Anti-Fibrotic Peptide Shows Early Promise Against Interstitial Lung DiseaseApril 13th, 2016
Grant Support
- Development of a Novel Therapeutic Agent for Skin FibrosisFIBROBIOLOGICS, LLC2024–2025
- Development of a Novel Therapeutic Agent for Skin FibrosisFIBROBIOLOGICS, LLC2024–2025
- Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary FibrosisFIBROBIOLOGICS, LLC2023–2025
- Clinical Trial: Apple StudyNational Center For Research Resources2008
- Administrative CoreNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2007
Professional Memberships
- Fellow
- Fellow
- other
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: